Unlocking the Therapeutic Potential of BCS Type II & IV Compounds: Oral Lipid-based Drug Delivery
|Event Date/Time: Sep 23, 2009||End Date/Time: Sep 23, 2010|
This webinar will focus on the importance of self-emulsification (dispersion) and lipolysis (digestion) properties for achieving acceptable â€œin-vivoâ€ performance of lipid-based formulations. Specifically, formulation parameters that are critical in the design of lipid-based fill systems for maintaining poorly water soluble drugs in solution throughout the GIT will be discussed.
An important aspect of this discussion is the use of â€œin-vitroâ€ methods that can be utilized to assess the dispersion and digestion properties of lipid-based formulations during development.
As a final topic, the selection of a suitable dosage form for the oral administration of lipid-based formulations will be discussed. Given that these formulations often do not lend themselves to conventional dosage form approaches due to their liquid or semi-solid nature, the advantages of the soft gelatin capsule dosage form for encapsulation of lipid-based systems will be presented.
The webinar will provide case studies of BCS Type II and IV compounds that have successfully utilized the formulation approaches presented by the speakers to improve oral bioavailability. A Q&A session will conclude the presentation.